1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-016, NCT00179647
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI 07-134, NCT00777881
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: UARK 2003-26, NCT00090493
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 19 to 70
Sponsor: Other
Protocol IDs: F080429003, UAB-0775, NCT00714259
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: CAN-NCIC-MY10, NCT00049673, NCIC-MY.10, CAN-NCIC-JMY10, ECOG-NCIC-JMY10, MY10
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI
Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: CALGB-100104, ECOG-CALGB-100104, NCT00114101
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: FHCRC-2004.00, 6004, MEDIMMUNE-FHCRC-2004.00, NCT00217438
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C05009, NCT00507416
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1A05, E1A05, NCT00522392
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: UARK 2006-66, NCT00572169
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-05, NCT00573391
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: 2006-15, NCT00574080
|
|
16.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1A06, E1A06, NCT00602641
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0777, S0777, NCT00644228
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 100241, NCT00657553
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 25009, 59306670 7R01CA115399, NCT00670631
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-020, NCT00689936
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 26866138 MMY 3021, NCT00722566
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2008-01, NCT00734877
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008_525, MK0683-088, NCT00773747
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: H8713, NCT00058825
|
